On January 4, 2021 Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported that Yutaka Niihara, M.D., M.P.H, Chairman and Chief Executive Officer of Emmaus, will present a company overview at the H.C. Wainwright BioConnect Conference, being held virtually, January 10-13, 2022 (Press release, EMMAC Life Sciences, JAN 4, 2022, https://www.prnewswire.com/news-releases/emmaus-life-sciences-to-present-at-the-hc-wainwright-bioconnect-conference-301453496.html [SID1234598144]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The on-demand presentation will be available beginning January 10, at 7:00 a.m. Eastern Time, on the "News and Events" section of Emmaus’ website at: View Source and will be archived for a period of 90 days after the conference.